Literature DB >> 19192256

JAL (RH48) blood group antigen: serologic observations.

Christine Lomas-Francis1, Denden Alcantara, Connie Westhoff, Joan Uehlinger, Marilia Valvasori, Lillian Castilho, Marion E Reid.   

Abstract

BACKGROUND: JAL (RH48) is a low-prevalence antigen in the Rh blood group system and anti-JAL has caused hemolytic disease of the newborn. JAL is associated with either a haplotype carrying depressed C and e antigens or one carrying depressed c and e antigens. Blood samples from JAL+ people were tested, published serologic findings were confirmed, serologic studies were extended to include expression of other Rh antigens, and the antibody specificities produced by three sensitized JAL+ probands are reported. STUDY DESIGN AND METHODS: Red blood cell (RBC) samples from 17 (12 probands) JAL+ persons were tested by hemagglutination using standard methods.
RESULTS: RBCs from both the Caucasian JAL+ probands had the (C)(e) haplotype and weakened C, e, hr(B), and hr(S) antigens. JAL+ samples from black persons had the (c)(e) haplotype and expressed weakened c, e, f, V, VS, hr(B), and hr(S) antigens. Plasma from three sensitized c+e+ JAL+ probands contained alloanti-c, alloanti-e, or alloantibody of apparent anti-Rh17 specificity. This study shows that this alloanti-Rh17-like antibody recognizes the high-prevalence antigen antithetical to JAL that has been named CEST.
CONCLUSIONS: The presence of the JAL antigen has a quantitative (weakening) effect on the expression of C, e, hr(B), and hr(S) antigens in Caucasian persons and of c, e, f, V, VS, hr(B), and hr(S) antigens in people of black African ancestry. A qualitative effect also was demonstrated by the presence of alloanti-c or alloanti-e in the plasma of two transfused c+e+ patients and by an antibody (anti-CEST) that recognizes the high-prevalence antigen antithetical to JAL.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19192256      PMCID: PMC2756138          DOI: 10.1111/j.1537-2995.2008.02025.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  8 in total

1.  Rare RHCE phenotypes in black individuals of Afro-Caribbean origin: identification and transfusion safety.

Authors:  France Noizat-Pirenne; Ketty Lee; Pierre-Yves Le Pennec; Philippe Simon; Philippe Kazup; Dora Bachir; Anne-Marie Rouzaud; Michele Roussel; Geneviève Juszczak; Cècile Ménanteau; Philippe Rouger; Rami Kotb; Jean-Pierre Cartron; Hélène Ansart-Pirenne
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

2.  A "NEW" RH ANTIBODY (ANTI-RH 26) WHICH DETECTS A FACTOR USUALLY ACCOMPANYING HR'.

Authors:  D W HUESTIS; M L CATINO; S BUSCH
Journal:  Transfusion       Date:  1964 Nov-Dec       Impact factor: 3.157

3.  A low-incidence red cell antigen JAL associated with two unusual Rh gene complexes.

Authors:  C Lomas; J Poole; N Salaru; M Redman; K Kirkley; M Moulds; J McCreary; G S Nicholson; H Hustinx; C Green
Journal:  Vox Sang       Date:  1990       Impact factor: 2.144

4.  The red cell antigen JAL in the Swiss population: family studies showing that JAL is an Rh antigen (RH48).

Authors:  J Poole; H Hustinx; H Gerber; C Lomas; Y W Liew; P Tippett
Journal:  Vox Sang       Date:  1990       Impact factor: 2.144

5.  Molecular basis of the LOCR (Rh55) antigen.

Authors:  Gail Coghlan; Marilyn Moulds; Edward Nylen; Teresa Zelinski
Journal:  Transfusion       Date:  2006-10       Impact factor: 3.157

6.  Involvement of Gly96 in the formation of the Rh26 epitope.

Authors:  B H Faas; P C Ligthart; C Lomas-Francis; M A Overbeeke; A E von dem Borne; C E van der Schoot
Journal:  Transfusion       Date:  1997 Nov-Dec       Impact factor: 3.157

Review 7.  The structure and function of the Rh antigen complex.

Authors:  Connie M Westhoff
Journal:  Semin Hematol       Date:  2007-01       Impact factor: 3.851

8.  The JAL antigen (RH48) is the result of a change in RHCE that encodes Arg114Trp.

Authors:  Connie M Westhoff; Sunitha Vege; Dwane Wylie; Pam Nickle; Christine Lomas-Francis; Kim Hue-Roye; Marion E Reid
Journal:  Transfusion       Date:  2008-12-23       Impact factor: 3.157

  8 in total
  7 in total

1.  Mutation in Rh48: Assessment for possible mutation prone point.

Authors:  Viroj Wiwanitkit
Journal:  Indian J Hematol Blood Transfus       Date:  2010-08-04       Impact factor: 0.900

2.  RHCE*ceTI encodes partial c and partial e and is often in cis to RHD*DIVa.

Authors:  Connie M Westhoff; Sunitha Vege; Christine Halter Hipsky; Kim Hue-Roye; Tamara Copeland; Randall W Velliquette; Trina Horn; Christine Lomas-Francis; Marion E Reid
Journal:  Transfusion       Date:  2012-07-13       Impact factor: 3.157

3.  A novel RHCE*ce 48C, 733G allele with Nucleotide 941C in Exon 7 encodes an altered red blood cell e antigen.

Authors:  Kim Hue-Roye; Christine Halter Hipsky; Randall W Velliquette; Akiko Fuchisawa; Christine Lomas-Francis; Carolyn Hoppe; Marion E Reid
Journal:  Transfusion       Date:  2011-01       Impact factor: 3.157

4.  RHCE*ceCF encodes partial c and partial e but not CELO, an antigen antithetical to Crawford.

Authors:  Christine Halter Hipsky; Christine Lomas-Francis; Akiko Fuchisawa; Marion E Reid; Marilyn Moulds; Joann Christensen; Pam Nickle; Sunitha Vege; Connie Westhoff
Journal:  Transfusion       Date:  2011-01       Impact factor: 3.157

5.  Red cells from the original JAL+ proband are also DAK+ and STEM+.

Authors:  K Hue-Roye; M E Reid; C M Westhoff; C Lomas-Francis
Journal:  Vox Sang       Date:  2011-04-08       Impact factor: 2.144

6.  The JAL antigen (RH48) is the result of a change in RHCE that encodes Arg114Trp.

Authors:  Connie M Westhoff; Sunitha Vege; Dwane Wylie; Pam Nickle; Christine Lomas-Francis; Kim Hue-Roye; Marion E Reid
Journal:  Transfusion       Date:  2008-12-23       Impact factor: 3.157

Review 7.  Genotyping in Sickle Cell Disease Patients: The French Strategy.

Authors:  Aline Floch; Christophe Tournamille; Btissam Chami; France Pirenne
Journal:  Transfus Med Hemother       Date:  2018-07-06       Impact factor: 3.747

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.